All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

CD80 Recombinant Monoclonal Antibody

Datasheet
Code CSB-RA246383A0HU
Size US$210
Order now
Image
  • Western Blot
    Positive WB detected in: Raji whole cell lysate
    All lanes: CD80 antibody at 1:2000
    Secondary
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 34, 30, 19 kDa
    Observed band size: 60 kDa
  • IHC image of CSB-RA246383A0HU diluted at 1:100 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
  • Immunoprecipitating CD80 in Raji whole cell lysate
    Lane 1: Rabbit control IgG instead of CSB-RA246383A0HU in Raji whole cell lysate. For western blotting,a HRP-conjugated Protein G antibody was used as the secondary antibody (1/2000)
    Lane 2: CSB-RA246383A0HU(2µg)+ Raji whole cell lysate(500µg)
    Lane 3: Raji whole cell lysate (10µg)
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
P33681
Target Names
CD80
Alternative Names
CD80; CD28LG; CD28LG1; LAB7; T-lymphocyte activation antigen CD80; Activation B7-1 antigen; BB1; CTLA-4 counter-receptor B7.1; B7; CD antigen CD80
Species Reactivity
Human
Immunogen
A synthesized peptide derived from human CD80
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
Rabbit IgG
Clone No.
3C3
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
Form
Liquid
Tested Applications
ELISA, WB, IHC, IP
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:50-1:200
IP 1:200-1:1000
Protocols
ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunoprecipitation (IP) Protocol
Troubleshooting and FAQs
Antibody FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

CD80, also known as B7-1, serves as a critical costimulatory molecule on antigen-presenting cells that shapes T cell activation and immune responses. By engaging CD28 or CTLA-4 on T lymphocytes, CD80 delivers signals that can either amplify or dampen immune activity, making it a central player in studies of immune checkpoint biology, autoimmunity, and cancer immunotherapy.

This recombinant rabbit monoclonal antibody, clone 3C3, offers the reproducibility and consistency that demanding immunology research requires. Because it is produced from a defined sequence rather than traditional hybridoma methods, researchers can expect reliable performance across experiments and between lots, eliminating a common source of variability in long-term studies.

The antibody has been validated across multiple applications, providing flexibility for different experimental approaches. Western blot analysis in Raji whole cell lysate detects CD80 at an observed molecular weight of approximately 60 kDa, which is notably higher than the predicted sizes of 30-34 kDa. This shift reflects the extensive glycosylation characteristic of CD80 as a cell surface immunoglobulin superfamily member. For tissue-based studies, immunohistochemistry has been optimized in paraffin-embedded human tonsil tissue, a lymphoid organ rich in CD80-expressing cells, with recommended dilutions between 1:50 and 1:100. The antibody also performs effectively in immunoprecipitation assays using Raji cell lysates, enabling protein interaction studies and complex isolation.

Supplied in a glycerol-containing buffer for stability at -20°C or -80°C, this antibody supports research into immune regulation, checkpoint biology, and stem cell immunology where consistent, sequence-defined reagents are essential for generating reproducible data.

Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

CD80 Antibodies

CD80 Proteins

CD80 ELISA kits

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Involved in the costimulatory signal essential for T-lymphocyte activation. T-cell proliferation and cytokine production is induced by the binding of CD28, binding to CTLA-4 has opposite effects and inhibits T-cell activation.; (Microbial infection) Acts as a receptor for adenovirus subgroup B.
Gene References into Functions
  1. Addition of TNFalpha to podocytes causes CD80 upregulation, actin reorganization and podocyte injury. PMID: 29022109
  2. Urinary CD80 levels were significantly higher in the children with minimal change disease than in the controls and patients with other causes of nephrotic syndrome. PMID: 29507273
  3. Results showed novel genetic associations with bone phenotypes and points to the CD80 gene as relevant in postmenopausal bone loss. PMID: 28466138
  4. Increased expressions of TLR-3, TLR-4 and CD80 mRNA and the level of urinary CD80/creatinine could be useful markers to differentiate patients of steroid-sensitive nephrotic syndrome in relapse from those with steroid-resistant nephrotic syndrome. PMID: 28210837
  5. The rs1915087 (C>T), rs6804441 (A>G) and rs41271391 (G>T) of B7 antigens were suspected as the factors associated with reduced risk of recurrent spontaneous abortion. PMID: 29069644
  6. Tregs were observed to regulate CD4(+), but not CD8(+), T cell infiltration into tumors through a CTLA-4/CD80 dependent mechanism. Disrupting CTLA-4 interaction with CD80 was sufficient to induce CD4 T cell infiltration into tumors. PMID: 28856392
  7. Results show that CD80 down-regulation is associated to aberrant DNA methylation in dysplasia of sporadic colonic carcinogenesis. This study indicates that the failure of immune surveillance mechanisms in non-inflammatory colon carcinogenesis may be linked to genomic methylation directly or indirectly affecting CD80 expression. PMID: 27377375
  8. Fabry disease is characterized by early occurrence of increased uCD80 excretion that appears to be a consequence of glycolipid accumulation. PMID: 27733175
  9. CTLA-4(+) microvesicles can competitively bind B7 costimulatory molecules on bystander dendritic cells, resulting in downregulation of B7 surface expression. PMID: 26979751
  10. The expression of B7-H6 is up-regulated in U87-derived glioma stem like cells. PMID: 27609569
  11. PD-1 receptor has a role in interacting with programmed cell death ligands and B7-1 PMID: 28270509
  12. CD80-QPAR platform provides a useful predictive model for unknown RA extract's bioactivities using the chemical fingerprint inputs PMID: 28337449
  13. this study shows that dendritic cells from rheumatoid arthritis patients have low expression levels of CD80 PMID: 27421624
  14. B7-1 is not expressed by podocytes in LN. A renoprotective effect of B7-1 blockade in LN patients cannot be ruled out but, if confirmed, cannot be the result of an effect on podocyte B7-1 PMID: 27198457
  15. analysis of CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease [review] PMID: 26409459
  16. Genetic interaction of CD80 and ALOX5AP was observed in systemic lupus erythematosus in Asian populations. PMID: 25862617
  17. Inhibitory Profile of Liver CD68+ Cells during HCV Infection as Observed by an Increased CD80 and PD-L1 but Not CD86 Expression PMID: 27065104
  18. Triple costimulation via CD80, 4-1BB, and CD83 ligand elicits the long-term growth of Vgamma9Vdelta2 T cells in low levels of IL-2. PMID: 26561569
  19. B7-1 is not induced in podocytes from patients with minimal change disease or focal segmental glomerulosclerosis. PMID: 26697986
  20. In the present study, we investigated the prognostic significance of the expression of three genes in the PD-L1 pathway, including PD-L1, B7.1 and PD-1, in three independent bladder cancer datasets in the Gene Expression Omnibus database. PMID: 25963805
  21. SNP rs1599795 in CD80 3'-UTR, through disrupting the regulatory role of miR-132-3p, miR-212-3p, and miR-361-5p in CD80 expression, contributed to the occurrence of gastric cancer. PMID: 24981235
  22. Meningococcal capsular polysaccharide-loaded vaccine nanoparticles induce expression of CD80. PMID: 24981893
  23. These findings reveal the distinct but complementary roles of CD80 and CD86 IgV and IgC domains in T cell activation. PMID: 24845157
  24. Expression of costimulatory molecules CD80/86 is an absolute requirement for efficient CD8 T cell priming by adenoviral vectors. PMID: 24951814
  25. Single-nucleotide polymorphisms in CD80 gene is associated with breast cancer risk after menopausal hormone replacement therapy. PMID: 24080446
  26. Data indicate that STAT5A and STAT5B transcription activator complex induces expression of CD80 gene. PMID: 24523507
  27. NOTCH1 protein regulates CD80/CD86-induced phosphatidylinositol 3-kinase signaling in interleukin-6 and indoleamine 2,3-dioxygenase production by dendritic cells PMID: 24415757
  28. lower expression on CD1c+ myeloid and CD303+ plasmacytoid DCs in pre-eclampsia PMID: 23773232
  29. No role in CD80 expression by podocytes was found for cytokines released by peripheral blood mononuclear cells PMID: 23689904
  30. Data indicate that low-dose decitabine (DAC) treatment can induce CD80 gene expression in a variety of cancer cells. PMID: 23671644
  31. These studies identify CD80-Fc as an alternative and potentially more efficacious therapeutic agent for overcoming PDL1-induced immune suppression and facilitating tumor-specific immunity PMID: 23918985
  32. Data indicate that the frequencies of CD11c, CD11c/CD86, HLA-DR/CD86, CD83 and CD80 were significantly high, while CD11c/HLA-DR was low in Hepatitis E infection. PMID: 23246582
  33. Lower expression of B7-1 and B7-2 proteins on peripheral monocytes in pre-eclampsia might indicate a secondary regulatory mechanism in response to the ongoing systemic maternal inflammation. PMID: 23289444
  34. he aim of this work was to analyse the interaction between early events in colonic ulcerative colitis-related and non-inflammatory carcinogenesis and CD80 expression to clarify what stimuli induce its up-regulation in these patients. PMID: 22704122
  35. mRNA expression analysis of B7-1 and NPHS1 in urinary sediment may be useful to differentiate between different histologic subtypes of glomerular kidney disease, particularly between minimal change disease and focal segmental glomerulosclerosis. PMID: 21414970
  36. Data suggest that expression of CD80, CD86, and CD40 on dendritic cells in normal endometrium is higher than on tumor infiltrating dendritic cells in endometrioid adenocarcinoma; this may reflect roles in antigen presentation/tumor escape. PMID: 22142817
  37. Data show that CD80 promoter and CD86 exon 8 allele frequencies vary significantly among populations of different ancestries. PMID: 22074996
  38. The interaction between PDL1 on antigen prresenting cells and B7.1 on T cells plays a dominant role in bidirectional interactions between these two molecules during alloimmune responses. PMID: 21697455
  39. the expression of the co-stimulatory molecule CD80 was decreased in intestines of celiac disease children after gluten-free diet. PMID: 21288140
  40. the costimulatory molecule CD80 prevents PDL1-mediated immune suppression by tumor cells and restores T cell activation PMID: 21555531
  41. Efficiency of GHA priming chemotherapy on refractory acute myeloid leukemia and myelodysplastic syndrome may be correlated with B7.1 expression. PMID: 18928583
  42. The low expression of CD80 and CD86 in thyroid papillary carcinoma may help them evade the immune system. PMID: 21469977
  43. study shows CTLA-4 can capture its ligands (CD80, CD86)from opposing cells by trans-endocytosis; data reveal mechanism of immune regulation in which CTLA-4 acts as an effector molecule to inhibit CD28 costimulation by cell-extrinsic depletion of ligands PMID: 21474713
  44. These results suggest that the polymorphisms of the CD86 gene may be used as genetic markers for making the diagnosis and prognosis of Graves' ophthalmopathy. PMID: 20884055
  45. Thalidomide can up-regulate the expression of B7-1 molecules on myeloma cells. PMID: 20034904
  46. increased CD80 and CD86 expression with the progression of tubulointerstitial lesion might play an important role in the development of lupus nephropathy PMID: 20979791
  47. B7-1 costimulation is required for induction and maintenance of lymphocytic choriomeningitis virus (LCMV)-specific CD8+ T cell memory, in T cell receptor (TCR)transgenic mice. PMID: 20601595
  48. B7-H1 and B7-1 significantly correlated with the pathological grade and tumor-node-metastasis (TNM) stage, respectively in pancreatic cancer. PMID: 20145927
  49. Data show that pollen grains triggered the production of IL-8, TNF-alpha, IL-6 and strongly upregulated the membrane expression of CD80, CD86, CD83, HLA-DR and caused only a slight increase in the expression of CD40. PMID: 20118277
  50. Thus, this study is the first demonstration of a distinct signaling event induced by CD80 and CD86 molecules in B cell lymphoma. PMID: 11726649

Show More

Hide All

Subcellular Location
Membrane; Single-pass type I membrane protein.
Tissue Specificity
Expressed on activated B-cells, macrophages and dendritic cells.
Database Links

HGNC: 1700

OMIM: 112203

KEGG: hsa:941

STRING: 9606.ENSP00000264246

UniGene: Hs.838

Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

Related Articles
With the High Potential in Cancer Immunotherapy, CD40 Is Triggering Attention Surface Markers That Help You Identify Lymphocytes 63.9% Objective Response Rate! B7-H3 Targeted Therapy Transforms Small Cell Lung Cancer Treatment, Domestic Players Compete in Hundred-Billion-Yuan Market What Are Immune Checkpoint Inhibitors? VSIG4: a Prominent B7 Family Costimulatory Molecule or Complement Receptor in Cancers and Inflammatory Diseases! Monoclonal Antibody Drugs Overview CRTAM: Class I Restricted T cell-associated Molecule, an Intriguing New Member of the Ig-SF Family! T Cell Activation - The Switch for T Cell Executive Function Pioneering CAR-T Cell Therapy: Advancing Personalized Cancer Treatment How Do CTLA-4 Inhibitors Work? A Complete Guide for Early-Career Researchers CD28: Molecular Mechanism and Therapeutic Progress of the Core Co-Stimulatory Receptor in T Cells CD40LG: A Key Molecule in Immune Regulation, Disease Associations and Therapeutic Progress Antibody FAQs What Is an Antibody? How to Choose an Antibody for Scientific Research? The difference between primary antibody and secondary antibod The Meaning of Irregular Antibody Screening Tag Antibodies, Your Good Partner in Protein Research How to Choose the Loading Control Antibodies?
Related pathways
Toll-like receptor signaling pathway Cell markers Target Therapy
CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*